Rare ALK expression but no ALK rearrangement in pancreatic ductal adenocarcinoma and neuroendocrine tumors

Rondell Graham, Andre M. Oliveira, Lizhi Zhang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

OBJECTIVES: Anaplastic lymphoma kinase (ALK) gene rearrangements were first identified in anaplastic large cell lymphomas. Subsequently, they have been observed in other tumor types with ALK-rearranged tumors demonstrating responsiveness to ALK inhibitors. The aggressiveness of pancreatic ductal adenocarcinoma warrants the examination of ALK rearrangements in pancreatic cancer as a potential therapeutic target. Immunohistochemical expression of ALK1 correlates with ALK rearrangements in other tumors. We performed ALK immunohistochemistry on samples of pancreatic ductal adenocarcinoma and pancreatic neuroendocrine tumors using 2 tissue microarrays. METHODS: ALK1 expression was scored for each case as 0, 1+, 2+, or 3+ using established criteria. Fluorescence in situ hybridization using a break-apart assay with probes for ALK was performed to detect ALK rearrangement in ALK1-positive cases. RESULTS: All 46 neuroendocrine tumors were negative for ALK1. Of 140 ductal adenocarcinoma cases, 5 showed immunoreactivity for ALK1: 1 was 3+, 2 were 2+, and 2 were 1+. However, fluorescence in situ hybridization for ALK rearrangement was negative in all 5 cases. CONCLUSIONS: The results demonstrate that ALK1 expression is uncommon in both pancreatic ductal adenocarcinoma and neuroendocrine tumors. Rare ALK1 expression is not induced by ALK translocation, and ALK is unlikely to be a therapeutic target in pancreatic tumors.

Original languageEnglish (US)
Pages (from-to)949-951
Number of pages3
JournalPancreas
Volume42
Issue number6
DOIs
StatePublished - Aug 2013

Fingerprint

Neuroendocrine Tumors
Adenocarcinoma
Fluorescence In Situ Hybridization
Neoplasms
anaplastic lymphoma kinase
Anaplastic Large-Cell Lymphoma
Gene Rearrangement
Pancreatic Neoplasms
Immunohistochemistry

Keywords

  • ALK
  • fluorescence in situ hybridization
  • gene rearrangement
  • pancreatic ductal adenocarcinoma
  • pancreatic neuroendocrine tumor

ASJC Scopus subject areas

  • Hepatology
  • Internal Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Rare ALK expression but no ALK rearrangement in pancreatic ductal adenocarcinoma and neuroendocrine tumors. / Graham, Rondell; Oliveira, Andre M.; Zhang, Lizhi.

In: Pancreas, Vol. 42, No. 6, 08.2013, p. 949-951.

Research output: Contribution to journalArticle

@article{4d98caa9647a4be29230800266933141,
title = "Rare ALK expression but no ALK rearrangement in pancreatic ductal adenocarcinoma and neuroendocrine tumors",
abstract = "OBJECTIVES: Anaplastic lymphoma kinase (ALK) gene rearrangements were first identified in anaplastic large cell lymphomas. Subsequently, they have been observed in other tumor types with ALK-rearranged tumors demonstrating responsiveness to ALK inhibitors. The aggressiveness of pancreatic ductal adenocarcinoma warrants the examination of ALK rearrangements in pancreatic cancer as a potential therapeutic target. Immunohistochemical expression of ALK1 correlates with ALK rearrangements in other tumors. We performed ALK immunohistochemistry on samples of pancreatic ductal adenocarcinoma and pancreatic neuroendocrine tumors using 2 tissue microarrays. METHODS: ALK1 expression was scored for each case as 0, 1+, 2+, or 3+ using established criteria. Fluorescence in situ hybridization using a break-apart assay with probes for ALK was performed to detect ALK rearrangement in ALK1-positive cases. RESULTS: All 46 neuroendocrine tumors were negative for ALK1. Of 140 ductal adenocarcinoma cases, 5 showed immunoreactivity for ALK1: 1 was 3+, 2 were 2+, and 2 were 1+. However, fluorescence in situ hybridization for ALK rearrangement was negative in all 5 cases. CONCLUSIONS: The results demonstrate that ALK1 expression is uncommon in both pancreatic ductal adenocarcinoma and neuroendocrine tumors. Rare ALK1 expression is not induced by ALK translocation, and ALK is unlikely to be a therapeutic target in pancreatic tumors.",
keywords = "ALK, fluorescence in situ hybridization, gene rearrangement, pancreatic ductal adenocarcinoma, pancreatic neuroendocrine tumor",
author = "Rondell Graham and Oliveira, {Andre M.} and Lizhi Zhang",
year = "2013",
month = "8",
doi = "10.1097/MPA.0b013e3182847bd0",
language = "English (US)",
volume = "42",
pages = "949--951",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Rare ALK expression but no ALK rearrangement in pancreatic ductal adenocarcinoma and neuroendocrine tumors

AU - Graham, Rondell

AU - Oliveira, Andre M.

AU - Zhang, Lizhi

PY - 2013/8

Y1 - 2013/8

N2 - OBJECTIVES: Anaplastic lymphoma kinase (ALK) gene rearrangements were first identified in anaplastic large cell lymphomas. Subsequently, they have been observed in other tumor types with ALK-rearranged tumors demonstrating responsiveness to ALK inhibitors. The aggressiveness of pancreatic ductal adenocarcinoma warrants the examination of ALK rearrangements in pancreatic cancer as a potential therapeutic target. Immunohistochemical expression of ALK1 correlates with ALK rearrangements in other tumors. We performed ALK immunohistochemistry on samples of pancreatic ductal adenocarcinoma and pancreatic neuroendocrine tumors using 2 tissue microarrays. METHODS: ALK1 expression was scored for each case as 0, 1+, 2+, or 3+ using established criteria. Fluorescence in situ hybridization using a break-apart assay with probes for ALK was performed to detect ALK rearrangement in ALK1-positive cases. RESULTS: All 46 neuroendocrine tumors were negative for ALK1. Of 140 ductal adenocarcinoma cases, 5 showed immunoreactivity for ALK1: 1 was 3+, 2 were 2+, and 2 were 1+. However, fluorescence in situ hybridization for ALK rearrangement was negative in all 5 cases. CONCLUSIONS: The results demonstrate that ALK1 expression is uncommon in both pancreatic ductal adenocarcinoma and neuroendocrine tumors. Rare ALK1 expression is not induced by ALK translocation, and ALK is unlikely to be a therapeutic target in pancreatic tumors.

AB - OBJECTIVES: Anaplastic lymphoma kinase (ALK) gene rearrangements were first identified in anaplastic large cell lymphomas. Subsequently, they have been observed in other tumor types with ALK-rearranged tumors demonstrating responsiveness to ALK inhibitors. The aggressiveness of pancreatic ductal adenocarcinoma warrants the examination of ALK rearrangements in pancreatic cancer as a potential therapeutic target. Immunohistochemical expression of ALK1 correlates with ALK rearrangements in other tumors. We performed ALK immunohistochemistry on samples of pancreatic ductal adenocarcinoma and pancreatic neuroendocrine tumors using 2 tissue microarrays. METHODS: ALK1 expression was scored for each case as 0, 1+, 2+, or 3+ using established criteria. Fluorescence in situ hybridization using a break-apart assay with probes for ALK was performed to detect ALK rearrangement in ALK1-positive cases. RESULTS: All 46 neuroendocrine tumors were negative for ALK1. Of 140 ductal adenocarcinoma cases, 5 showed immunoreactivity for ALK1: 1 was 3+, 2 were 2+, and 2 were 1+. However, fluorescence in situ hybridization for ALK rearrangement was negative in all 5 cases. CONCLUSIONS: The results demonstrate that ALK1 expression is uncommon in both pancreatic ductal adenocarcinoma and neuroendocrine tumors. Rare ALK1 expression is not induced by ALK translocation, and ALK is unlikely to be a therapeutic target in pancreatic tumors.

KW - ALK

KW - fluorescence in situ hybridization

KW - gene rearrangement

KW - pancreatic ductal adenocarcinoma

KW - pancreatic neuroendocrine tumor

UR - http://www.scopus.com/inward/record.url?scp=84880656085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880656085&partnerID=8YFLogxK

U2 - 10.1097/MPA.0b013e3182847bd0

DO - 10.1097/MPA.0b013e3182847bd0

M3 - Article

C2 - 23851431

AN - SCOPUS:84880656085

VL - 42

SP - 949

EP - 951

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 6

ER -